You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

The Nurse View: Clinical Considerations in the use of PARP inhibitors for Ovarian Cancer

  • Authors: Beth Y. Karlan, MD; Paula J. Anastasia, RN, MN, AOCN; Kimberly Halla, MSN, FNP-C
  • CE Released: 3/28/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/28/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses who manage patients with ovarian cancer undergoing treatment with PARP inhibitors.

The goal of this activity is to improve knowledge and competence of management of patients with ovarian cancer undergoing treatment with PARP inhibitors.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Use of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer
  • Have greater competence related to
    • Developing strategies to mitigate adverse effects related to treatment with PARP inhibitors
    • Outlining patient resources and strategies that will help patients understand their disease and what to expect from treatment


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Beth Y. Karlan, MD

    Professor, Cedar-Sinai Medical Center, Los Angeles, California

    Disclosures

    Disclosure: Beth Y. Karlan, MD, has disclosed no relevant financial relationships.

    Dr Karlan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Karlan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Paula J. Anastasia, RN, MN, AOCN

    Clinical Nurse Specialist, Cedars-Sinai Medical Center, Los Angeles, California

    Disclosures

    Disclosure: Paula J. Anastasia, RN, MN, AOCN, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Clovis Oncology; Genentech, Inc.

    Ms Anastasia does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Anastasia does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Kimberly Halla, MSN, FNP-C

    Nurse Practitioner, Division of Gynecology Oncology, Arizona Oncology, Phoenix, Arizona

    Disclosures

    Disclosure: Kimberly Halla, MSN, FNP-C, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Heron Therapeutics, Inc.
    Served as a speaker or a member of a speakers bureau for: Clovis Oncology

    Ms Halla does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Halla does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Sara Fagerlie, PhD, CHCP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

  • Lori K. Pender, PharmD, MPH, BCOP

    Freelance Editor

    Disclosures

    Disclosure: Lori K. Pender, PharmD, MPH, BCOP, has disclosed no relevant financial relationships.

Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

The Nurse View: Clinical Considerations in the use of PARP inhibitors for Ovarian Cancer

Authors: Beth Y. Karlan, MD; Paula J. Anastasia, RN, MN, AOCN; Kimberly Halla, MSN, FNP-CFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 3/28/2018

Valid for credit through: 3/28/2019

processing....

 
 
 
 

Educational Impact Challenge

The goal of this activity is to improve knowledge and competence in the management of patients with ovarian cancer undergoing treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print